Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rima McLeod

Showing results (11-20 of 102) with videos related to

Pageof 11
Sort By:
Antimicrobial Agents and Chemotherapy|December 25, 2013
Spiroindolone that inhibits PfATPase4 is a potent, cidal inhibitor of Toxoplasma gondii tachyzoites in vitro and in vivoYing Zhou, Alina Fomovska, Stephen Muench, et al.
The Pediatric Infectious Disease Journal|September 30, 2011
Severe congenital toxoplasmosis in the United States: clinical and serologic findings in untreated infantsTudor Rares Olariu, Jack S Remington, Rima McLeod, et al.
American Journal of Ophthalmology|June 6, 2003
Ophthalmic outcomes after prenatal and postnatal treatment of congenital toxoplasmosisAntoine P Brézin, Philippe Thulliez, Jacques Couvreur, et al.
Acta Crystallographica. Section D, Biological Crystallography|July 2, 2003
Expression, purification and crystallization of the Plasmodium falciparum enoyl reductaseStephen P Muench, John B Rafferty, Rima McLeod, et al.
The Pediatric Infectious Disease Journal|March 3, 2006
Severe sulfadiazine hypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitisRima McLeod, Asif Rashid Khan, Gwendolyn A Noble, et al.
Memorias Do Instituto Oswaldo Cruz|May 12, 2009
Host genetic and epigenetic factors in toxoplasmosisSarra E Jamieson, Heather Cordell, Eskild Petersen, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 15, 2012
Molecular target validation, antimicrobial delivery, and potential treatment of Toxoplasma gondii infectionsBo-Shiun Lai, William H Witola, Kamal El Bissati, et al.
Vaccine|November 25, 2010
Towards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A*0201Hua Cong, Ernest J Mui, William H Witola, et al.
International Journal for Parasitology|January 29, 2002
Genetic analysis of influences on survival following Toxoplasma gondii infectionJennifer Johnson, Yasuhiro Suzuki, Douglas Mack, et al.
Immunome Research|December 7, 2010
Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondiiHua Cong, Ernest J Mui, William H Witola, et al.
Pageof 11

Showing results (11-20 of 102) with videos related to

Sort By:
Pageof 11
Antimicrobial Agents and Chemotherapy|December 25, 2013
Spiroindolone that inhibits PfATPase4 is a potent, cidal inhibitor of Toxoplasma gondii tachyzoites in vitro and in vivoYing Zhou, Alina Fomovska, Stephen Muench, et al.
The Pediatric Infectious Disease Journal|September 30, 2011
Severe congenital toxoplasmosis in the United States: clinical and serologic findings in untreated infantsTudor Rares Olariu, Jack S Remington, Rima McLeod, et al.
American Journal of Ophthalmology|June 6, 2003
Ophthalmic outcomes after prenatal and postnatal treatment of congenital toxoplasmosisAntoine P Brézin, Philippe Thulliez, Jacques Couvreur, et al.
Acta Crystallographica. Section D, Biological Crystallography|July 2, 2003
Expression, purification and crystallization of the Plasmodium falciparum enoyl reductaseStephen P Muench, John B Rafferty, Rima McLeod, et al.
The Pediatric Infectious Disease Journal|March 3, 2006
Severe sulfadiazine hypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitisRima McLeod, Asif Rashid Khan, Gwendolyn A Noble, et al.
Memorias Do Instituto Oswaldo Cruz|May 12, 2009
Host genetic and epigenetic factors in toxoplasmosisSarra E Jamieson, Heather Cordell, Eskild Petersen, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 15, 2012
Molecular target validation, antimicrobial delivery, and potential treatment of Toxoplasma gondii infectionsBo-Shiun Lai, William H Witola, Kamal El Bissati, et al.
Vaccine|November 25, 2010
Towards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A*0201Hua Cong, Ernest J Mui, William H Witola, et al.
International Journal for Parasitology|January 29, 2002
Genetic analysis of influences on survival following Toxoplasma gondii infectionJennifer Johnson, Yasuhiro Suzuki, Douglas Mack, et al.
Immunome Research|December 7, 2010
Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondiiHua Cong, Ernest J Mui, William H Witola, et al.
Pageof 11